financetom
Business
financetom
/
Business
/
Stran Receives Another Nasdaq Noncompliance Notice
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Stran Receives Another Nasdaq Noncompliance Notice
Nov 22, 2024 2:13 PM

04:59 PM EST, 11/22/2024 (MT Newswires) -- Stran ( SWAG ) was notified by Nasdaq that the company is not in compliance with exchange listing requirements because of the delay in filing Form 10-Q for the quarter ended Sept. 30.

The company also failed to file 10-Q reports on time for the quarters ended March 31 and June 30 and got an exception until Dec. 16 to file those reports.

Dec. 6 is the deadline to submit to Nasdaq an updated plan to regain compliance with listing rules, the company said Friday in a statement.

"The company intends to submit the required update to its plan and take the necessary steps to regain compliance with Nasdaq listing rules as soon as practicable," according to the statement.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Spotify to Begin Paying Video Podcasters
Market Chatter: Spotify to Begin Paying Video Podcasters
Nov 15, 2024
07:03 AM EST, 11/14/2024 (MT Newswires) -- Spotify Technology ( SPOT ) plans to start paying makers of popular video podcasts to appear on its platform, Bloomberg reported Wednesday, citing Spotify's ( SPOT ) chief executive officer, Daniel Ek. It will also soon offer its paid subscribers ways to watch without ads, the report said. Spotify ( SPOT ) seeks...
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
GSK Reports Positive Results from Phase 3 Trial for Blenrep in Multiple Myeloma Treatment
Nov 15, 2024
07:05 AM EST, 11/14/2024 (MT Newswires) -- GSK (GSK) said Thursday that the interim analysis of the DREAMM-7 head-to-head phase three trial evaluating Blenrep, or belantamab mafodotin, in combination with bortezomib plus dexamethasone, or BorDex, as a second-line or later treatment for relapsed or refractory multiple myeloma showed positive headline results. The trial met its key secondary endpoint of overall...
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Cash-strapped US farmers switch to generic crop chemicals, in blow to big manufacturers
Nov 15, 2024
(Reuters) - U.S. farmers struggling with slumping incomes and depressed grain prices have been switching to cheaper generic pesticides and fungicides as they plan for spring planting next year, which market analysts said could hit the bottom lines of agrichemical companies like Bayer. Signs of these financial impacts are already emerging. Bayer shares fell sharply to a 20-year low on...
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
AtkinsRealis Q3 Adjusted Profit, Revenue Increase
Nov 15, 2024
07:03 AM EST, 11/14/2024 (MT Newswires) -- AtkinsRealis ( SNCAF ) on Thursday said third-quarter adjusted profit and revenue rose. The engineering services and nuclear company said adjusted profit attributable to shareholders from professional services and project management (PS&PM) increased 64% to $110.1 million, or $0.63 per diluted share, from $67.3 million, or $0.38 per diluted share, last year. Services...
Copyright 2023-2026 - www.financetom.com All Rights Reserved